Company: OPGN
Filing Date: 2025-08-21
Form Type: 10-K
Source: 0001829126-25-006628
Chunk: 1163

Company: OPGEN INC
Filing Date: 2025-08-21
Form: 10-K
Item: Item 6
Chunk 1163
---
ortization
     
    Operating expenses

    280

    3,362

    Interest expense
     
    Other expenses

    -

    -

    Total lease costs

    $
    234,264

    $
    585,363

Other lease information as of December 31, 2024 is as follows:

    Schedule of other information

    Other Information
     
    Total

    Weighted average remaining lease term (in years)

    Operating leases

    7.2

    Finance leases

    -

    Weighted average discount rate:

    Operating leases

    10.0
    %
  
    Finance leases

    -

    F-32

Supplemental cash flow information as of the years ended December 31, 2024 and 2023 is as follows:

    Schedule of supplemental cash flow information

    Supplemental Cash Flow Information
     
    2024

    2023

    Cash paid for amounts included in the measurement of lease liabilities

    Cash used in operating activities

    Operating leases
     
    $
    233,984

    $
    582,001

    Finance leases
     
    $
    -

    $
    -

    Cash used in financing activities

    Finance leases
     
    $
    280

    $
    3,364

    ROU assets obtained in exchange for lease obligations:

    Operating leases
     
    $
    -

    $
    801,321

Note 12 – License Agreements, Research Collaborations and Development Agreements

Sandoz

In December 2018, Ares Genetics entered into a service frame agreement with Sandoz International GmbH (“Sandoz”), to leverage Ares Genetics’ database on the genetics of antibiotic resistance, ARESdb, and the ARES Technology Platform for Sandoz’ anti-infective portfolio.

Under the terms of the framework agreement, which had an initial term of 36 months and was subsequently extended to January 31, 2025, Ares Genetics and Sandoz intended to develop a digital anti-infectives platform, combining established microbiology laboratory methods with advanced bioinformatics and artificial intelligence methods to support drug development and life-cycle management. The collaboration, in the short- to mid-term, aimed to both rapidly and cost-effectively re-purpose existing antibiotics and design value-added medicines with the objective of expanding indication areas and to overcome antibiotic resistance, in particular with regards to infections with bacteria that have already